-
公开(公告)号：US10308702B2
公开(公告)日：2019-06-04
申请号：US15218699
申请日：2016-07-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Glen Eugene Mikesell , Han Chang , Robert James Peach
IPC: C07K14/705 , C07K16/28 , C07K19/00 , A61K38/17 , A61K39/395 , G01N33/50 , A61K38/00 , A61K39/00
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
-
12.发明授权公开(公告)号：US10052360B2
公开(公告)日：2018-08-21
申请号：US15047849
申请日：2016-02-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Robert Cohen , Suzette Belder-Carr , David Hagerty , Robert James Peach , Jean-Claude Becker
IPC: C07K14/705 , A61K38/17 , A61K39/00 , A61K39/395 , A61K47/48 , A61K38/00
CPC classification number: A61K38/1774 , A61K38/00 , A61K39/0008 , A61K39/395 , A61K47/6811 , C07K14/70521 , C07K2319/00
Abstract: The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
-
公开(公告)号：US10590183B2
公开(公告)日：2020-03-17
申请号：US16382620
申请日：2019-04-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Glen Eugene Mikesell , Han Chang , Robert James Peach
IPC: C07K14/705 , A61K38/16 , C07K16/28 , C07K19/00 , A61K38/17 , A61K39/395 , G01N33/50 , A61K38/00 , A61K39/00
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
-
公开(公告)号：US09399052B2
公开(公告)日：2016-07-26
申请号：US14177641
申请日：2014-02-11
Applicant: Bristol-Myers Squibb Company
Inventor： Glen Eugene Mikesell , Henry Shen , Han Chang , Joshua N. Finger , Guchen Yang , Robert James Peach
IPC: C07H21/04 , C07K14/705 , A61K38/17 , C07K16/28 , C07K19/00 , A61K39/395 , A61K38/00 , A61K39/00
CPC classification number: C07K14/70532 , A61K38/00 , A61K38/1774 , A61K39/39533 , A61K2039/505 , C07K16/2827 , C07K19/00 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/10 , C07K2319/30 , C07K2319/40 , G01N33/5005 , Y02A50/396
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
Abstract translation: 本发明提供编码调节免疫或炎症反应细胞如T细胞的活化的B7相关因子的核酸。 还提供了包含编码B7相关多肽（包括BSL1，BSL2和BSL3）的核酸的表达载体和融合构建体。 本发明进一步提供分离的B7相关多肽，分离的包含B7相关多肽的融合蛋白，以及与B7相关多肽特异性反应的抗体或其部分。 此外，本发明提供利用B7相关核酸，多肽或肽的测定法。 本发明还提供可用于人或动物受试者的免疫调节的B7相关核酸，多肽，融合蛋白或抗体的组合物。
-
15.发明授权Methods for treating scleroderma by administering a soluble CTLA4 molecule 有权通过施用可溶性CTLA4分子治疗硬皮病的方法公开(公告)号：US09296808B2
公开(公告)日：2016-03-29
申请号：US14193687
申请日：2014-02-28
Applicant: Bristol-Myers Squibb Company
Inventor： Robert Cohen , Suzette Belder-Carr , David Hagerty , Robert James Peach , Jean-Claude Becker
IPC: C07K14/705 , A61K39/395 , A61K38/00 , A61K39/00
CPC classification number: A61K38/1774 , A61K38/00 , A61K39/0008 , A61K39/395 , A61K47/6811 , C07K14/70521 , C07K2319/00
Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
Abstract translation: 本发明涉及通过向受试者施用阻断内源性B7分子结合其配体的CTLA4分子来治疗自身免疫疾病如硬皮病的组合物和方法。
-
Patent Agency Ranking
16.发明申请METHODS FOR TREATING SCLERODERMA BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE 审中-公开通过管理可溶性CTLA4分子来治疗SCLERODERMA的方法公开(公告)号：US20140286948A1
公开(公告)日：2014-09-25
申请号：US14193687
申请日：2014-02-28
Applicant: Bristol-Myers Squibb Company
Inventor： Robert COHEN , Suzette Belder-Carr , David Hagerty , Robert James Peach , Jean-Claude Becker
IPC: C07K14/705
CPC classification number: A61K38/1774 , A61K38/00 , A61K39/0008 , A61K39/395 , A61K47/6811 , C07K14/70521 , C07K2319/00
Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
Abstract translation: 本发明涉及通过向受试者施用阻断内源性B7分子结合其配体的CTLA4分子来治疗自身免疫性疾病如硬皮病的组合物和方法。
-
17.发明申请公开(公告)号：US20140154260A1
公开(公告)日：2014-06-05
申请号：US14177641
申请日：2014-02-11
Applicant: Bristol-Myers Squibb Company
Inventor： Glen Eugene MIKESELL , Henry Shen , Han Chang , Joshua N. Finger , Guchen Yang , Robert James Peach
IPC: C07K14/705 , A61K38/17 , C07K16/28 , A61K39/395
CPC classification number: C07K14/70532 , A61K38/00 , A61K38/1774 , A61K39/39533 , A61K2039/505 , C07K16/2827 , C07K19/00 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/10 , C07K2319/30 , C07K2319/40 , G01N33/5005 , Y02A50/396
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
Abstract translation: 本发明提供编码调节免疫或炎性反应细胞如T细胞活化的B7相关因子的核酸。 还提供了包含编码B7相关多肽（包括BSL1，BSL2和BSL3）的核酸的表达载体和融合构建体。 本发明进一步提供分离的B7相关多肽，分离的包含B7相关多肽的融合蛋白，以及与B7相关多肽特异性反应的抗体或其部分。 此外，本发明提供利用B7相关核酸，多肽或肽的测定法。 本发明还提供可用于人或动物受试者的免疫调节的B7相关核酸，多肽，融合蛋白或抗体的组合物。
-
公开(公告)号：US10400023B2
公开(公告)日：2019-09-03
申请号：US15229582
申请日：2016-08-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Glen Eugene Mikesell , Han Chang , Robert James Peach
IPC: C07K16/28 , C07K14/705 , A61K38/00
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
-
公开(公告)号：US20190185538A1
公开(公告)日：2019-06-20
申请号：US16227601
申请日：2018-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Robert James Peach , Joseph Naemura , Peter S. Linsley , Jurgen Bajorath
IPC: C07K14/725 , C07K14/705 , A61K38/17 , A61K39/39 , C07H21/04 , C12N5/0783 , A61K39/395
CPC classification number: C07K14/7051 , A61K38/00 , A61K38/1774 , A61K39/39 , A61K39/3955 , A61K2039/505 , C07H21/04 , C07K14/70521 , C07K2319/30 , C12N5/0636 , C12N2501/51
Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
-
公开(公告)号：US20170190759A1
公开(公告)日：2017-07-06
申请号：US15218699
申请日：2016-07-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Glen Eugene MIKESELL , Han Chang , Robert James Peach
IPC: C07K14/705 , G01N33/50 , C07K16/28
CPC classification number: C07K14/70532 , A61K38/00 , A61K38/1774 , A61K39/39533 , A61K2039/505 , C07K16/2827 , C07K19/00 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/10 , C07K2319/30 , C07K2319/40 , G01N33/5005 , Y02A50/396
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.049 seconds)
